Applications of Yttrium-90 (Y) in Hepatocellular Carcinoma

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2024 Feb 28

PMID 38414759

Authors

Zhonghao Jiang

Fan Yang

Wanxiang Wang

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, affecting millions of people worldwide. Due to the lack of systemic radiation therapy in hepatocellular carcinoma, researchers have been investigating the use of yttrium-90 (Y) radioembolization for local-regional tumor control since the 1960s. With the development of glass and resin Y microspheres and the durable local control, good long-term efficacy, and equivalent tumor responsiveness and tolerability of Y-selective internal irradiation compared with alternative therapies such as transarterial chemoembolization (TACE) and sorafenib, Y radioembolization has gradually been applied in the treatment of hepatocellular carcinoma of all stages. In this article, we summarize the latest progress of Y in the treatment of hepatocellular carcinoma in terms of its principle, advantages, indications, contraindications, efficacy and adverse effects.

Citing Articles

Evaluation of long axial field-of-view (LAFOV) PET/CT for post-treatment dosimetry in Yttrium-90 radioembolization of liver tumors: a comparative study with conventional SPECT imaging.

Zeimpekis K, Sari H, Gozlugol N, Achangwa N, Shi K, Schindewolf M Eur J Nucl Med Mol Imaging. 2024; 52(4):1460-1471.

PMID: 39730786 PMC: 11839895. DOI: 10.1007/s00259-024-07034-9.

Tc/Y radiolabeled biodegradable gel microspheres for lung shutting fraction assessment and radioembolization in hepatocellular carcinoma theranostics.

Dong Y, Yin L, Huang J, Hu D, Sun J, Zhang Z Mater Today Bio. 2024; 29:101367.

PMID: 39687798 PMC: 11647226. DOI: 10.1016/j.mtbio.2024.101367.

References

Filippi L, Schillaci O, Cianni R, Bagni O . Yttrium-90 resin microspheres and their use in the treatment of intrahepatic cholangiocarcinoma. Future Oncol. 2017; 14(9):809-818. DOI: 10.2217/fon-2017-0443. View

Yan C, Wang Y, Yu Q, Cheng X, Zhang B, Li B . Clonorchis sinensis excretory/secretory products promote the secretion of TNF-alpha in the mouse intrahepatic biliary epithelial cells via Toll-like receptor 4. Parasit Vectors. 2015; 8:559. PMC: 4620022. DOI: 10.1186/s13071-015-1171-0. View

Poty S, Francesconi L, McDevitt M, Morris M, Lewis J . α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 1. J Nucl Med. 2018; 59(6):878-884. PMC: 6004557. DOI: 10.2967/jnumed.116.186338. View

Jeyarajah D, Doyle M, Espat N, Hansen P, Iannitti D, Kim J . Role of yttrium-90 selective internal radiation therapy in the treatment of liver-dominant metastatic colorectal cancer: an evidence-based expert consensus algorithm. J Gastrointest Oncol. 2020; 11(2):443-460. PMC: 7212103. DOI: 10.21037/jgo.2020.01.09. View

Hilgard P, Hamami M, El Fouly A, Scherag A, Muller S, Ertle J . Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010; 52(5):1741-9. DOI: 10.1002/hep.23944. View

Abdel-Rahman O, Elsayed Z . Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev. 2020; 11:CD011313. PMC: 8215872. DOI: 10.1002/14651858.CD011313.pub4. View

Hamad A, Aziz H, Kamel I, Diaz D, Pawlik T . Yttrium-90 Radioembolization: Current Indications and Outcomes. J Gastrointest Surg. 2022; 27(3):604-614. DOI: 10.1007/s11605-022-05559-8. View

Levillain H, Bagni O, Deroose C, Dieudonne A, Gnesin S, Grosser O . International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging. 2021; 48(5):1570-1584. PMC: 8113219. DOI: 10.1007/s00259-020-05163-5. View

Murthy R, Nunez R, Szklaruk J, Erwin W, Madoff D, Gupta S . Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics. 2005; 25 Suppl 1:S41-55. DOI: 10.1148/rg.25si055515. View

10.

Gabr A, Kulik L, Mouli S, Riaz A, Ali R, Desai K . Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort. Hepatology. 2020; 73(3):998-1010. DOI: 10.1002/hep.31318. View

11.

Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C . Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology. 2012; 57(5):1826-37. DOI: 10.1002/hep.26014. View

12.

Salem R, Lewandowski R, Mulcahy M, Riaz A, Ryu R, Ibrahim S . Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2009; 138(1):52-64. DOI: 10.1053/j.gastro.2009.09.006. View

13.

Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, De Baere T . Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2020; 6(1):17-29. DOI: 10.1016/S2468-1253(20)30290-9. View

14.

Kulik L, Vouche M, Koppe S, Lewandowski R, Mulcahy M, Ganger D . Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma. J Hepatol. 2014; 61(2):309-17. DOI: 10.1016/j.jhep.2014.03.023. View

15.

Kodaira S, Morokoshi Y, Keiko Li H, Konishi T, Kurano M, Hasegawa S . Evidence of Local Concentration of α-Particles from At-Labeled Antibodies in Liver Metastasis Tissue. J Nucl Med. 2018; 60(4):497-501. PMC: 6448461. DOI: 10.2967/jnumed.118.216853. View

16.

Campbell A, Bailey I, Burton M . Analysis of the distribution of intra-arterial microspheres in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol. 2000; 45(4):1023-33. DOI: 10.1088/0031-9155/45/4/316. View

17.

Wang E, Broadwell S, Bellavia R, Stein J . Selective internal radiation therapy with SIR-Spheres in hepatocellular carcinoma and cholangiocarcinoma. J Gastrointest Oncol. 2017; 8(2):266-278. PMC: 5401864. DOI: 10.21037/jgo.2016.11.08. View

18.

Giammarile F, Bodei L, Chiesa C, Flux G, Forrer F, Kraeber-Bodere F . EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2011; 38(7):1393-406. DOI: 10.1007/s00259-011-1812-2. View

19.

Kim H, Kim G . Radiation pneumonitis following Yttrium-90 radioembolization: A Korean multicenter study. Front Oncol. 2023; 13:977160. PMC: 9885146. DOI: 10.3389/fonc.2023.977160. View

20.

Gupta A, Gordon A, Gabr A, Kalyan A, Kircher S, Mahalingam D . Yttrium-90 Radioembolization of Unresectable Intrahepatic Cholangiocarcinoma: Long-Term Follow-up for a 136-Patient Cohort. Cardiovasc Intervent Radiol. 2022; 45(8):1117-1128. DOI: 10.1007/s00270-022-03183-2. View